EGFR and lung carcinoma: Compared with the lung cancer HCC827 cells in the control group, the icotinib treatment group inhibited the activation of the downstream MAPK/ERK signaling pathway by inhibiting the autophosphorylation of EGFR, and it also inhibited the proliferation of HCC827 cells [47].